Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Active not recruiting 4Terminated 1Recruiting 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 1

Interventions

pembrolizumab 33Carboplatin 18Cisplatin 15Nivolumab 14Pemetrexed 12Paclitaxel 12Ipilimumab 11atezolizumab 10Gemcitabine 10venetoclax 9Radiotherapy 9Docetaxel 9durvalumab 8Cyclophosphamide 8fludarabine 7Specimen Handling 7Biopsy 7Bevacizumab 7tislelizumab 6enzalutamide 6Trastuzumab 6Practice Guidelines as Topic 6Cetuximab 6tazemetostat 5fludarabine phosphate 5Surveys and Questionnaires 5Standard of Care 5Radiosurgery 5Magnetic Resonance Spectroscopy 5Injections 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × 2C4 antibody × 90 days × Clear all
NCT03199885 2026-05-29

Testing the Drug Atezolizumab or Placebo With Usual Therapy in First-Line HER2-Positive Metastatic Breast Cancer

National Cancer Institute (NCI)

Phase 3 Terminated
190 enrolled 13 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡